My guess is that the venue they are referring to is ASCO. This does not mean that the FDA is not already aware of the results today and at anytime will not recommend an immediate advancement of Kevetrin into a phase 2 or 3 for ovarian or pancreatic or another hard to treat cancer - of course that is major speculation on my part.
When mathematics and data are used in prediction we call this an 'educated guess'.
So, for those that might think I am daydreaming at $800 CTIX, please at least agree to call it 'educated daydreaming'.